NIH RePORTER
Cure8 regulatory brief
Why This Matters
A test that identifies trigger foods from the esophagus could reduce the need for repeated endoscopies and make dietary treatment for EoE more accurate, affordable, and patient-friendly.
Who Should Pay Attention
Patients with eosinophilic esophagitis; gastroenterologists; allergists; clinical researchers interested in diet-based interventions and biomarkers.
Study Snapshot
Story typeRegulatory
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
The study will compare an EAT-guided elimination diet versus a sham diet to see whether IgA food-specific antibodies from esophageal secretions predict trigger foods and reduce esophageal eosinophilia and symptoms.
Investigators will also evaluate serum food-specific antibodies, kappa light chains, and new food frequency questionnaires as less-invasive biomarkers to monitor exposure and disease activity. The project is a pilot/feasibility study intended to optimize the EAT assay, collect biomarker data, and inform sample-size and design for larger trials.
It is funded and led by an academic team with expertise in EoE, allergy, nutrition, pathology, and microbiome bioinformatics.
Keep In Mind
This is a funded pilot/feasibility project record on NIH Reporter describing planned research; it does not present trial outcomes. The EAT assay and serum biomarkers are experimental and under evaluation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsKathryn A Peterson
InstitutionUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedSep 7, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - R01DK141696 - $308,000
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Novel Immunological-Directed Live Biotherapy Product for Treating Crohn's Disease
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
The role of microbiota specific T cells in Inflammatory Bowel Disease
This project aims to map microbe-specific T cells in Crohn's disease using single-cell RNA and TCR sequencing. Findings could reveal antigen-specific mechanisms driving IBD and help lay groundwork for targeted...
Defining the origins and effector function of avb6-specific autoantibodies in ulcerative colitis
Researchers found that nearly all people with UC have high-titer autoantibodies to the epithelial integrin αvβ6 that can precede disease and associate with worse outcomes. Understanding whether and how these antibodies...